Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | STK10 | O94804 | 1/20 | 0.32 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349967 | 0.89 | MAPT (0.51) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL352304 | 0.86 | HTR7 (0.36) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10177366 | 0.82 | SMN1; SMN2 (0.34) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL351208 | 0.80 | DHFR (0.32) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL24535255 | 0.78 | — | — | |
| SCHEMBL370175 | 0.73 | MAOA (0.39) | KDM4E | |
| SCHEMBL30316893 | 0.72 | MAPT (0.42) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10177387 | 0.72 | ABL1 (0.36) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL352252 | 0.72 | HTT (0.33) | MAPTKMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL10177371 | 0.72 | MEN1 (0.31) | MEN1KMT2ASMN1; SMN2RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | claimed |
| US-8895737-B2 | Process for preparing antiviral compounds | ABBVIE INC. | 2014-11-25 | — | — | US | claimed |
| EP-3415504-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2018-12-19 | — | — | EP | disclosed |
| EP-2887941-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | disclosed |
| EP-3056486-B1 | PROCESS FOR PREPARING INTERMEDIATES FOR ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | disclosed |
| US-9732045-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160332973-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. | 2016-11-17 | — | — | US | disclosed |
| US-9434698-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | disclosed |
| EP-3056486-A2 | PROCESS FOR PREPARING INTERMEDIATES FOR ANTIVIRAL COMPOUNDS | AbbVie Bahamas Ltd. (BS) | 2016-08-17 | — | — | EP | disclosed |
| US-9255074-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-07-09 | — | — | US | disclosed |
| EP-2887941-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | AbbVie Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| US-8895737-B2 | Process for preparing antiviral compounds | ABBVIE INC. | 2014-11-25 | — | — | US | disclosed |
| WO-2014031791-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2593439-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009699-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | MAPT 4064/4885MEN1 3566/4885KMT2A 4487/4885 |
| US-20160332973-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | MAPT 4064/4885MEN1 3566/4885KMT2A 4487/4885 |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, MAVS, RNASE1 | MAPT 4108/4885MEN1 3497/4885KMT2A 4435/4885 |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | MAPT 4064/4885MEN1 3566/4885KMT2A 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.